BioMerieuxFRA:EYWN +2.46%84 5-Year Yield-on-Cost % is 4.80 as of Jul. 12, 2026, which is 122% above its 10-year median of 2.16. GuruFocus rates FRA:EYWN with a GF Score™ of 84/100 and a GF Value™ of €111.64 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 65 Medical Diagnostics & Research companies, BioMerieux ranks better than 67.69% on this metric.
BioMerieux's yield on cost for the quarter that ended in Dec. 2025 was 4.80.
The historical rank and industry rank for BioMerieux's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:EYWN'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.52 Med: 2.16 Max: 4.8
Current: 4.8
During the past 13 years, BioMerieux's highest Yield on Cost was 4.80. The lowest was 0.52. And the median was 2.16.
FRA:EYWN's 5-Year Yield-on-Cost % is ranked better than 67.69% of 65
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.42
vs FRA:EYWN: 4.80
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
BioMerieux 5-Year Yield-on-Cost % Related Terms
FRA:EYWN vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, BioMerieux's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMerieux 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BioMerieux's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where BioMerieux's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of BioMerieux is calculated as
BioMerieux (FRA:EYWN) has a 5-Year Yield-on-Cost % of 4.80 as of Jul. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on BioMerieux and its competitors. This is 122% above median its historical median of 2.16. Over the past decade, BioMerieux's 5-Year Yield-on-Cost % has ranged from 0.52 to 4.80. According to the industry distribution chart, BioMerieux ranks #21 out of 65 companies in the Medical Diagnostics & Research industry, placing it in the top 32.3%.
Is BioMerieux's 5-Year Yield-on-Cost % too high?
BioMerieux's current 5-Year Yield-on-Cost % of 4.80 is 122% above median its 10-year median of 2.16. Over the past 10 years, this metric has ranged from a low of 0.52 to a high of 4.80. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.42. BioMerieux's value of 4.80 is 98.3% above this industry median. Based on the distribution chart, BioMerieux ranks #21 out of 65 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, BioMerieux has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMerieux's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BioMerieux ranks #21 out of 65 companies for 5-Year Yield-on-Cost %. This puts BioMerieux in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.42. BioMerieux's value of 4.80 is 98.3% above this benchmark. Historically, BioMerieux's own 5-Year Yield-on-Cost % has ranged from 0.52 to 4.80 over the past decade. While the company's 10-year median is 2.16 vs. the industry median of 2.42, BioMerieux has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.42, based on 65 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioMerieux's current 5-Year Yield-on-Cost % of 4.80 is 98.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on BioMerieux and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioMerieux's current 5-Year Yield-on-Cost % is 4.80, which is 122% above median its own 10-year median of 2.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMerieux stock overvalued right now?
Based on GuruFocus' analysis, BioMerieux (FRA:EYWN) is currently considered Significantly Undervalued. The stock's GF Value™ is €111.64, compared to a current price of €70.80 — trading 36.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 4.80, which is 122% above median its 10-year median of 2.16 and 98.3% above the Medical Diagnostics & Research industry median of 2.42. BioMerieux's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For BioMerieux (FRA:EYWN), the current 5-Year Yield-on-Cost % is 4.80 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMerieux (FRA:EYWN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued.
The current stock price of €70.80 is trading 36.6% below its estimated GF Value™ of €111.64.
GuruFocus considers BioMerieux to be Significantly Undervalued.
Key valuation signals for FRA:EYWN:
5-Year Yield-on-Cost %: 4.80 (122% above median its 10-year median of 2.16)
GF Value™: €111.64 vs. price of €70.80 (36.6% below fair value)
Industry Position: 98.3% above the Medical Diagnostics & Research median (#21 of 65)
No single metric tells the full story. See the FRA:EYWN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
84GF Score
Get the complete analysis for FRA:EYWN
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EYWN has been successfully added to your 